Senseonics Holdings (SENS) Reports Q4 Loss Senseonics (SENS) delivered earnings and revenue surprises of 33.33% and 0%, respectively, for the quarter ended December 2024. Do the…
Senseonics Holdings, Inc. Reports Fourth Quarter and Full Year 2024 Financial Results Received FDA approval for Eversense® 365 Continuous Glucose Monitoring system and launched Eversense 365 with commercial partner, Ascensia…
Senseonics Holdings, Inc. to Participate in the TD Cowen 45th Annual Health Care Conference GERMANTOWN, Md., Feb. 13, 2025 (GLOBE NEWSWIRE) -- Senseonics Holdings, Inc. (NYSE American: SENS), a medical technology company…
Senseonics Holdings, Inc. Announces Business Updates Including Preliminary 2024 Results, 365 Launch Update and Cancellation of Special Meeting GERMANTOWN, Md., Jan. 08, 2025 (GLOBE NEWSWIRE) -- Senseonics Holdings, Inc. (NYSE American: SENS), a medical technology company…
Senseonics (SENS) Deal With Mercy to Drive Eversense CGM Sales Senseonics Holdings (SENS) collaborates with Mercy to bring its Eversense CGM to a healthcare system that is likely to drive…